Company Overview
Deep Health AI India Limited (formerly Deep Diamond India Limited) reported its 32nd Annual Report for FY 2025-2026, showcasing significant corporate and financial developments. The company held its AGM on September 30, 2026 to approve financial statements and various resolutions including auditor appointment and director remuneration changes.
Financial Performance
The company demonstrated strong revenue growth with standalone revenue from operations increasing to ₹4.25 crore in FY26 from ₹1.25 crore in FY25, representing a 237.55% increase. Profit after tax stood at ₹1.29 crore compared to ₹0.86 crore previously. The company declared and paid an interim dividend of ₹1.35 crore with additional tax of ₹0.89 crore on dividend distribution. Consolidated financial statements showed net profit of ₹1.13 crore with EPS of ₹0.12.
Capital Structure & Corporate Actions
A major rights issue was completed during the year, issuing 9.61 crore equity shares at ₹4.16 per share (including premium of ₹3.16), raising total proceeds of ₹39.98 crore. The authorized share capital was increased from ₹15 crore to ₹50 crore. The company also changed its name from Deep Diamond India Limited to Deep Health AI India Limited effective February 9, 2026 and shifted its registered office from Maharashtra to Rajasthan.
Investments & Divestments
The company significantly increased investments in quoted equities to ₹36.34 crore (book value) with fair market value of ₹27.40 crore as of March 31, 2026. The company divested its investment in joint venture Hemonc Pharma Private Limited and initiated the striking off process for wholly-owned subsidiary Microcure Biotech Private Limited. The company holds a 33.33% interest in associate company Ferry Automotive Private Limited.
Exceptional Items & Legal Matters
An exceptional item of ₹5.77 crore was recognized related to the failed acquisition of Oasis Ceramics Private Limited under IBC proceedings. The company had paid ₹0.55 crore earnest money deposit and ₹2 crore acquisition consideration, faced bank guarantee invocation of ₹0.03 crore, and has a pending NCLT application for time extension.
Board & Management Changes
Significant board composition changes occurred with Mr. Narayan Singh Rathore appointed as Managing Director & Chairperson and Mrs. Laveena Pokharna as Whole-Time Director & CFO. Mr. Rakesh Vishnoi was appointed as Company Secretary & Compliance Officer. The board also saw the cessation of Mr. Kailash Chandra (Independent Director) and Mr. Narendra Kumar Shrimali.
Segment Performance
The company operates in two segments: Diamond Jewellery (no revenue in FY26) and Pharmaceuticals (consultancy fees of ₹4.25 crore in FY26). Key ratios showed improvement with current ratio at 19.34 (vs 3.04 previously) and debt equity ratio at 0.01.
Shareholding & Corporate Governance
As of March 31, 2026, the company had 14.42 crore equity shares with 99.08% dematerialized holdings. The company maintained proper corporate governance structures with appointed secretarial and internal auditors, and a constituted Sexual Harassment Committee that received no complaints during the year.